Replies to post #405822 on Amarin Corp Plc (AMRN)

[CaptBeer]

He didn't mention it but the REDUCE-IT Trial made up 1/4 of the patients in the study and BTW REDUCE-IT demonstrated 39% reduction in hsCRP. The more interesting thing about this study was that it was co-authored by Dr. Sour Grapes (Nissen). He just may be softening his stance against VASCEPA.

[dogn]

Ridker is advocating for Esperion’s BA (Bempedoic Acid - Nexletol) and was lead author of recent CLEAR harmony paper

https://pace-cme.org/bempedoic-acid/

https://www.sciencedirect.com/science/article/abs/pii/S1933287423000326

Journal of Clinical Lipidology
Available online 14 February 2023

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Paul M Ridker MD, Lei Lei PhD, Kausik K. Ray MD, Christie M. Ballantyne MD, Gary Bradwin MS, Nader Rifai PhD

This study was sponsored by Esperion Therapeutics, Inc.

ClinicalTrials.gov Identifier: NCT02666664; https://clinicaltrials.gov/ct2/show/NCT02666664.